184 related articles for article (PubMed ID: 37901209)
21. Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone.
Krug C; Birkholz K; Paulus A; Schwenkert M; Schmidt P; Hoffmann N; Hombach A; Fey G; Abken H; Schuler G; Schuler-Thurner B; Dörrie J; Schaft N
Cancer Immunol Immunother; 2015 Dec; 64(12):1623-35. PubMed ID: 26515978
[TBL] [Abstract][Full Text] [Related]
22. Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy.
Nota SPFT; Osei-Hwedieh DO; Drum DL; Wang X; Sabbatino F; Ferrone S; Schwab JH
Front Oncol; 2022; 12():939166. PubMed ID: 36110930
[TBL] [Abstract][Full Text] [Related]
23. PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo.
Liao Q; Mao Y; He H; Ding X; Zhang X; Xu J
Biomark Res; 2020 Nov; 8(1):57. PubMed ID: 33292688
[TBL] [Abstract][Full Text] [Related]
24. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
25. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
26. The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma.
Simon B; Wiesinger M; März J; Wistuba-Hamprecht K; Weide B; Schuler-Thurner B; Schuler G; Dörrie J; Uslu U
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30103488
[TBL] [Abstract][Full Text] [Related]
27. Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma.
Sahin A; Sanchez C; Bullain S; Waterman P; Weissleder R; Carter BS
PLoS One; 2018; 13(7):e0199414. PubMed ID: 29975720
[TBL] [Abstract][Full Text] [Related]
28. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
[No Abstract] [Full Text] [Related]
29. Chimeric antigen receptor T-cell therapy for melanoma.
Razavi A; Keshavarz-Fathi M; Pawelek J; Rezaei N
Expert Rev Clin Immunol; 2021 Mar; 17(3):209-223. PubMed ID: 33481629
[TBL] [Abstract][Full Text] [Related]
30. Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients.
Yu J; Wu X; Yan J; Yu H; Xu L; Chi Z; Sheng X; Si L; Cui C; Dai J; Ma M; Xu T; Kong Y; Guo J
J Hematol Oncol; 2018 Jan; 11(1):1. PubMed ID: 29298689
[TBL] [Abstract][Full Text] [Related]
31. Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4.
Chauhan J; Grandits M; Palhares LCGF; Mele S; Nakamura M; López-Abente J; Crescioli S; Laddach R; Romero-Clavijo P; Cheung A; Stavraka C; Chenoweth AM; Sow HS; Chiaruttini G; Gilbert AE; Dodev T; Koers A; Pellizzari G; Ilieva KM; Man F; Ali N; Hobbs C; Lombardi S; Lionarons DA; Gould HJ; Beavil AJ; Geh JLC; MacKenzie Ross AD; Healy C; Calonje E; Downward J; Nestle FO; Tsoka S; Josephs DH; Blower PJ; Karagiannis P; Lacy KE; Spicer J; Karagiannis SN; Bax HJ
Nat Commun; 2023 Apr; 14(1):2192. PubMed ID: 37185332
[TBL] [Abstract][Full Text] [Related]
32. Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19/CD20 chimeric antigen receptor T cells.
Wang Y; Zhong K; Ke J; Chen X; Chen Y; Shu W; Chen C; Hu S; Sun X; Huang H; Luo C; Liu L; Yang J; Zhang Y; Zhi H
Cytotherapy; 2021 Aug; 23(8):715-723. PubMed ID: 33863641
[TBL] [Abstract][Full Text] [Related]
33. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
34. Decitabine-Mediated Upregulation of CSPG4 in Ovarian Carcinoma Cells Enables Targeting by CSPG4-Specific CAR-T Cells.
Harrer DC; Schenkel C; Berking C; Herr W; Abken H; Dörrie J; Schaft N
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291817
[TBL] [Abstract][Full Text] [Related]
35. Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade.
Koopmans I; Hendriks MAJM; van Ginkel RJ; Samplonius DF; Bremer E; Helfrich W
J Invest Dermatol; 2019 Nov; 139(11):2343-2351.e3. PubMed ID: 31128201
[TBL] [Abstract][Full Text] [Related]
36. CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma.
Price MA; Colvin Wanshura LE; Yang J; Carlson J; Xiang B; Li G; Ferrone S; Dudek AZ; Turley EA; McCarthy JB
Pigment Cell Melanoma Res; 2011 Dec; 24(6):1148-57. PubMed ID: 22004131
[TBL] [Abstract][Full Text] [Related]
37. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.
Lanitis E; Poussin M; Klattenhoff AW; Song D; Sandaltzopoulos R; June CH; Powell DJ
Cancer Immunol Res; 2013 Jul; 1(1):43-53. PubMed ID: 24409448
[TBL] [Abstract][Full Text] [Related]
38. Opportunities and obstacles for the melanoma immunotherapy using T cell and chimeric antigen receptor T (CAR-T) applications: a literature review.
Bahmanyar M; Vakil MK; Al-Awsi GRL; Kouhpayeh SA; Mansoori H; Mansoori Y; Salahi A; Nikfar G; Tavassoli A; Behmard E; Moravej A; Ghasemian A
Mol Biol Rep; 2022 Nov; 49(11):10627-10633. PubMed ID: 35715610
[TBL] [Abstract][Full Text] [Related]
39. Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead.
Soltantoyeh T; Akbari B; Karimi A; Mahmoodi Chalbatani G; Ghahri-Saremi N; Hadjati J; Hamblin MR; Mirzaei HR
Cells; 2021 Jun; 10(6):. PubMed ID: 34207884
[TBL] [Abstract][Full Text] [Related]
40. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.
Luangwattananun P; Junking M; Sujjitjoon J; Wutti-In Y; Poungvarin N; Thuwajit C; Yenchitsomanus PT
Breast Cancer Res Treat; 2021 Feb; 186(1):25-36. PubMed ID: 33389403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
